Fig. 3From: A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trialsSensitivity analysis. Progression-free survival†by treatment in the normal weight (a), overweight (b), and obese (c) cohort, with chemoimmunotherapy treatment effect estimates††by BMI category (d)†Kaplan-Meier product limit estimates were derived from the pooled cohort of two RCTs. Blue: chemoimmunotherapy; Red: chemotherapy††Forest plot estimates (chemoimmunotherapy versus chemotherapy) were derived from stratified (by RCT) Cox proportional hazards regression models with a BMI-by-treatment interaction termBack to article page